Featured Research

from universities, journals, and other organizations

Study Finds Immune Therapy For Metastatic Breast Cancer Possible

Date:
September 1, 2004
Source:
NIH/National Cancer Institute
Summary:
Researchers at the National Cancer Institute (NCI), one of the National Institutes of Health, have found promising evidence that immune cell transplant therapy can help shrink tumors in patients with metastatic breast cancer.

Researchers at the National Cancer Institute (NCI), one of the National Institutes of Health, have found promising evidence that immune cell transplant therapy can help shrink tumors in patients with metastatic breast cancer. Similar therapies, which also involve transplantation of donated immune cells, have produced dramatic anti-tumor effects in leukemias and lymphomas--cancers of the blood and lymph, respectively. However, previous studies have not proven that such therapies have clinical effects on breast cancer.

Michael Bishop, M.D., of NCI, led the study, which was published on August 16 on the Web site of the Journal of Clinical Oncology.* Scientists at the Experimental Transplantation and Immunology Branch of NCI's Center for Cancer Research studied 16 women with breast cancer that had progressed to an average of three metastatic sites after conventional treatments, including chemotherapy and hormones; six of these women had tumor shrinkage after cellular immune therapy.

Bishop's group gave study patients a treatment similar to a bone marrow transplant. Each patient received cells donated by a sibling. This transplant included lymphocytes -- cells crucial to the immune system -- and the adult stem cells that produce blood cells. The active, anti-tumor component of this cellular immune therapy regimen was a class of lymphocytes called T cells, which attack and kill tumor cells.

The same qualities that make transplanted T cells react against tumors --especially their pugnacious tendency to attack foreign cells -- also make them dangerous to the transplant recipient. Because the recipient's own immune system may attack donor cells, NCI scientists gave subjects an immune-suppressing chemotherapy regimen before the transplant. To help protect subjects' bodies from the toxic effects of the transplant, scientists followed the chemotherapy with a course of transplant-conditioning drugs.

Each subject received transplants with the same concentration of T cells. The initial transplants had a relatively low concentration of these cells; infusions given at 42, 70, and 98 days after the first transplant had exponentially increasing numbers of T cells. Increasing the concentration over this time period helped NCI researchers isolate patients' reactions to the transplant from their reaction to the chemotherapy, and established T cells as the active element in the transplant.

Six patients of the 16 had partial or minor responses to the treatment lasting an average of three months. The transplants had a toxic effect in many of the women, causing not only anti-tumor activity but also attacking normal cells. This graft-vs.-host disease (GVHD) was observed in a majority of subjects: 10 had acute GVHD; of 13 available for a follow-up examination, four had chronic GVHD.

"Although it was hoped that the women would garner clinical benefit from this research, the study was not designed to demonstrate that this immune cell therapy results in an improvement of outcome, specifically survival," Bishop explained.

"The study demonstrated that immune-based therapies, specifically the lymphocyte-based therapy we used, could result in tumor regression," Bishop said. However, it is crucial to improve cellular immune therapy by lowering the risk of toxic effects, especially GVHD. Collaborating laboratories are currently testing specialized T cells they hope will cause little GVHD while retaining strong anti-tumor effects.

"These data provide support to continue efforts to develop better immune-based therapies to augment currently available therapies for metastatic breast cancer," stated Bishop. Such advancement is critical, as current chemotherapies for the disease result in an average survival of only 24 months.

###

* Bishop, MR, Gress R. "Allogeneic Lymphocytes Induce Tumor Regression of Advanced Metastatic Breast Cancer." Journal of Clinical Oncology. Vol. 22, number 19. October 1, 2004.


Story Source:

The above story is based on materials provided by NIH/National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Cancer Institute. "Study Finds Immune Therapy For Metastatic Breast Cancer Possible." ScienceDaily. ScienceDaily, 1 September 2004. <www.sciencedaily.com/releases/2004/09/040901091331.htm>.
NIH/National Cancer Institute. (2004, September 1). Study Finds Immune Therapy For Metastatic Breast Cancer Possible. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2004/09/040901091331.htm
NIH/National Cancer Institute. "Study Finds Immune Therapy For Metastatic Breast Cancer Possible." ScienceDaily. www.sciencedaily.com/releases/2004/09/040901091331.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pregnancy Spacing Could Have Big Impact On Autism Risks

Pregnancy Spacing Could Have Big Impact On Autism Risks

Newsy (Oct. 1, 2014) A new study says children born less than one year and more than five years after a sibling can have an increased risk for autism. Video provided by Newsy
Powered by NewsLook.com
Robotic Hair Restoration

Robotic Hair Restoration

Ivanhoe (Oct. 1, 2014) A new robotic procedure is changing the way we transplant hair. The ARTAS robot leaves no linear scarring and provides more natural results. Video provided by Ivanhoe
Powered by NewsLook.com
Insertable Cardiac Monitor

Insertable Cardiac Monitor

Ivanhoe (Oct. 1, 2014) A heart monitor the size of a paperclip that can save your life. The “Reveal Linq” allows a doctor to monitor patients with A-Fib on a continuous basis for up to 3 years! Video provided by Ivanhoe
Powered by NewsLook.com
Attacking Superbugs

Attacking Superbugs

Ivanhoe (Oct. 1, 2014) Two weapons hospitals can use to attack superbugs. Scientists in Ireland created a new gel resistant to superbugs, and a robot that can disinfect a room in minutes. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins